AuI-incorporated metal-organic frameworks nanozymes for thioreduction and glutathione depletion-mediated efficient photoimmunotherapy

J Colloid Interface Sci. 2024 Dec 10;683(Pt 1):552-563. doi: 10.1016/j.jcis.2024.12.057. Online ahead of print.

Abstract

Tumor therapy has historically been a global research focus, with phototherapy garnered significant attention as a innovative treatment modality. However, the antioxidant defense system in the tumor microenvironment, characterized by excessive glutathione (GSH) and thiol-containing proteins, often limits the effectiveness of photodynamic therapy. In this study, we report the development of a new multifunctional integrated nanozyme with thioredoxin reductase-oxidase (TrxRox) and GSH-oxidase (GSHox)-like activities. This nanozyme, termed AuI-incorporated MOFs, was synthesized by embedding monovalent Au nanozymes into a light-sensitive metal-organic framework (MOFs) structure using an in-situ oxidation-reduction method. The intergrated AuI nanozyme exhibited inhibitory effects on TrxR and presented significant anti-tumor properties. Moreover, the integrated nanozyme also demonstrates peroxidase-like activity, catalyzing the decomposition of hydrogen peroxide (H2O2) into hydroxyl radicals (•OH). Additionally, this nanomedicine effectively depletes existing GSH and TrxR, thereby enhancing the efficacy of photodynamic and photothermal therapy. Notably, under light conditions, this nanozyme induces oxidative stress within cells, leading to apoptosis and necrosis of tumor cells. Of note, it triggers immunogenic cell death and activating antigen-presenting cells to convert cold tumors into hot tumors. Therefore, AuI-incorporated MOFs nanozyme demonstrates promising potential in photoimmunotherapy, offering new insights and strategies for tumor therapy.

Keywords: Au(I)-incorporated MOFs; Glutathione depletion; Nanozyme; Photoimmunotherapy; Thioreduction.